

UCSF

UC San Francisco Previously Published Works

Title

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.

Permalink

<https://escholarship.org/uc/item/5h77d38w>

Authors

Bryce, Alan
Crawford, E
Agarwal, Neeraj
[et al.](#)

Publication Date

2024-04-01

DOI

10.1097/ju9.000000000000138

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed



HHS Public Access

Author manuscript

JU Open Plus. Author manuscript; available in PMC 2024 May 21.

Published in final edited form as:

JU Open Plus. 2024 April ; 2(4): . doi:10.1097/ju9.000000000000138.

This is an open-access article distributed under the terms of the [Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 \(CCBY-NC-ND\)](#), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Corresponding Author: Alan H. Bryce, Department of Oncology, City of Hope Cancer Center, AZ 85338 (alan.bryce@coh.org).

CONFLICTS OF INTEREST

The authors declare the following competing interests: Alan H. Bryce has received compensation for a consulting or advisory role from Merck, Janssen, Astellas, AstraZeneca, Pfizer, Myovant, and Lantheus; and grant funding from Janssen. Andrew J. Armstrong has received compensation for a consulting or advisory role from Astellas, Epic Sciences, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Clovis, Exact Sciences, Myovant, Exelixis, GoodRx, and Novartis; and his institution has received research funding from Astellas, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Amgen, and Novartis. Andrei Iagaru has received compensation for a consulting or advisory role from Alpha9Tx, Clarity Pharmaceuticals, Novartis, Progenics, Radionetics, RayzeBio, and Telix; and research/grant funding from GE Healthcare and Novartis. Ana M. Aparicio has received compensation for a consulting or advisory role from Pfizer, Janssen, and Bristol Myers Squibb. Alicia K. Morgans has received compensation for a consulting or advisory role from Astellas, AstraZeneca, AAA, Bayer, Janssen, Exelixis, Myovant, Myriad Genetics, Lantheus, Novartis, Merck, Pfizer, Telix, and Sanofi; and research funding from Bayer, Astellas, Myovant, Pfizer, Sanofi, and Janssen. Brian F. Chapin has received compensation for a consulting or advisory role from Blue Earth Diagnostics, Astellas, Pfizer, and Janssen; and is a clinical trial investigator for Regeneron and Blue Earth Therapeutics. Daniel P. Petrylak has received compensation for a consulting or advisory role from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Ipsen, Janssen, Merck & Company Inc, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi Aventis Pharmaceuticals, Seattle Genetics, and Urogen; has received grant support from Ada Cap (Advanced Accelerator Applications), Agensys Inc, Arvinas, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo Company Limited, Eisai, Eli Lilly, Endocyte, Ferring, Genentech, Gilead Sciences, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, and Seattle Genetics; and has owned stock in Bellicum and Tyme. Daniel E. Spratt has received compensation for a consulting or advisory role from AstraZeneca, Bayer, Boston Scientific, Elekta, Janssen, Novartis, Pfizer, and Varian. Emmanuel S. Antonarakis has received compensation for a consulting or advisory role from Sanofi, Dendreon, Janssen Biotech, ESSA, Merck, AstraZeneca, Clovis Oncology, Lilly, Bayer, Amgen, Astellas Pharma, Blue Earth Diagnostics, Bristol Myers Squibb/Celgene, Constellation Pharmaceuticals, Curium Pharma, Exact Sciences, Foundation Medicine, GlaxoSmithKline, InVita, Ismar Health Care, Medivation, Tempus, Orion, and Alkido Pharma; he has received research funding from Celgene and Clovis Oncology; his institution has received research funding from Janssen Biotech, Johnson & Johnson, Sanofi, Dendreon, Aragon Pharmaceuticals, Exelixis, Millennium, Genentech, Novartis, Astellas Pharma, Tokai Pharmaceuticals, Merck, AstraZeneca, Clovis Oncology, Constellation Pharmaceuticals, Celgene, and Clovis Oncology; and he is co-inventor of a biomarker technology that has been licensed to Qiagen. E. David Crawford has received compensation for a consulting or advisory role from Janssen, Bayer, MDx, Tolmar, Pfizer, and Astellas; has received research/grant funding from the NIH and University of Colorado Cancer Center; and has received compensation for a leadership position from Carden Jennings. Eric Small has received compensation for a consulting or advisory role from Janssen, Fortis, and Deciphera; received honoraria from Janssen and Johnson & Johnson; and owns stock/stock options in Fortis, Harpoon, and Teon. Evan Y. Yu has received compensation for a consulting or advisory role from Aadi Bioscience, Advanced Accelerator Applications, Bayer, Janssen, Merck, and Oncternal; and his institution has received research funding from Bayer, Blue Earth, Daiichi-Sankyo, Dendreon, Lantheus, Merck, Seagen, Surface, Taiho, and Tyra. Felix Y. Feng has received compensation for a consulting or advisory role from Astellas, Bayer, Blue Earth Diagnostics, Janssen, Myovant, Novartis, Roivant, Sanofi, Tempus, Artera, BMS (Tumor Microenvironment Group), ClearNote, and Serimmune. Himisha Beltran has received compensation for a consulting or advisory role from Janssen, Merck, Pfizer, Foundation Medicine, Blue Earth Diagnostics, Amgen, Bayer, Oncorus, LOXO, Daicchi Sankyo, Sanofi, Curie Therapeutics, Fusion Pharma, AstraZeneca, and Novartis; and her institution has received research funding from Janssen, Bristol Myers Squibb, Circle Pharma, Daicchi Sankyo, and Novartis. Jeremie Calais has received compensation for a consulting, advisory, or blinded image reading role from Advanced Accelerator Applications, Amgen, Astellas, Bayer, Blue Earth Diagnostics Inc, Curium Pharma, DS Pharma, GE Healthcare, Isoray, IBA RadioPharma, Janssen Pharmaceuticals, Monrol, Lightpointmedical, Lantheus, Novartis, Pfizer, POINT biopharma, Progenics, Radiomedix, Sanofi, Siemens-Varian, SOFIE, and Telix Pharmaceuticals; and grant funding from the Prostate Cancer Foundation. John W. Davis has received research funding from Janssen. Katie S. Murray has received compensation for a consulting or advisory role from Curium and Urogen Pharma. Michael S. Cookson has received compensation for a consulting or advisory role from LynxDx, Natera, Bayer, Consulting JW, Remedica Medical Education & Publishing, Pfizer, Lantheus, Nonagen Bioscience Corp, MJH LifeSciences, Pacific Edge Diagnostics USA Ltd, Janssen, Prokarium, BioPharm Communications, Myovant, Merck, Clinical Education Alliance, TesoRx Pharma; and has received research support from Ferring Pharmaceutical and MDXHealth. Maha H. Hussain has received compensation for a consulting or advisory role from GSK, Novartis, and Bayer; honoraria for educational event or lecture from Merck, Mubarak Mahdi Almansour (Chairman, International Genitourinary Cancer Conference), MJH, and Academic CME; her institution has received research/grant funding from AstraZeneca and Arvinas. Michael Morris has received compensation for a consulting or advisory role from AstraZeneca, Lantheus, Daiichi, Convergent Therapeutics, Pfizer, ITM Isotope Technologies, Clarity Pharmaceuticals, Blue Earth Diagnostics, POINT Biopharma, Telix, and Z-Alpha; he is an uncompensated advisor to Bayer and Novartis; his institution has received research funding from Bayer, Concept, Roche, Janssen, Celgene, Novartis, and Astellas. Matthew B. Rettig has received compensation for a consulting or advisory role from Myovant, INmune Bio, Bayer, and Johnson & Johnson; is a member of the Speakers' Bureau for Johnson & Johnson

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

Alan H. Bryce¹, E. David Crawford², Neeraj Agarwal³, Maha H. Hussain⁴, Himisha Beltran⁵, Matthew R. Cooperberg⁶, Daniel P. Petrylak⁷, Neal Shore⁸, Daniel E. Spratt⁹, Scott T. Tagawa¹⁰, Emmanuel S. Antonarakis¹¹, Ana M. Aparicio¹², Andrew J. Armstrong¹³, Thomas P. Boike¹⁴, Jeremie Calais¹⁵, Michael A. Carducci¹⁶, Brian F. Chapin¹⁷, Michael S. Cookson¹⁸, John W. Davis¹⁷, Tanya Dorff¹⁹, Scott E. Eggener²⁰, Felix Y. Feng²¹, Martin Gleave²², Celestia Higano²³, Andrei Iagaru²⁴, Alicia K. Morgans²⁵, Michael Morris²⁶, Katie S. Murray²⁷, Wendy Poage²⁸, Matthew B. Rettig^{29,30}, Oliver Sartor³¹, Howard I. Scher²⁶, Paul Sieber³², Eric Small³³, Sandy Srinivas³⁴, Evan Y. Yu³⁵, Tian Zhang³⁶, Phillip J. Koo³⁷

¹Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona

and Bayer; and has received grants/research support from Merck, Lantheus, Progenics, Clovis, ORIC, Pfizer, Novartis, Amgen. Neeraj Agarwal has received compensation for a consulting or advisory role from Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics; his institution has received research funding from Amivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracoon. Neal Shore has received compensation for a consulting or advisory role from *AbbVie, Alesia Therapeutics, Akido, Amgen, Arquer, Asieris, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, Clarity, Clovis, Cold Genesys, Dendreon, Exact Images, Exact Sciences, FerGene, FIZE Medical, GConcology, GenesisCare, Genetech, Guardant, Ferring, Foundation Medicine, ImmunityBio, Incyte, Invitae, Janssen, Lantheus, Lilly, MDX, Merck, Minomic, Myovant, Myriad, NGM, Nonagen, Novartis, NYMOX, Pacific Edge, Photocure, Pfizer, PlatformQ, Profound, Promaxo, Propella, Protara, Sanofi, SesenBio, Speciality Networks, Telix, Tolmar, Urogen, Vaxiion, and Vessi*; received payment for expert testimony from *Ferring*; and is on the board of *Photocure*. Oliver Sartor has received compensation for a consulting or advisory role from Advanced Accelerator Applications, Amgen, ART BioScience, Astellas Pharma, AstraZeneca, Bayer, Clarity Pharmaceuticals, EMD Serono, Fusion Pharmaceuticals, Isotopen Technologien, Janssen, MacroGenics, Novartis, Pfizer, Point Biopharma, Ratio, Sanofi, Telix Pharmaceuticals, and TeneoBio; he has stock or other ownership interested with *AbbVie, Cardinal Health, Clarity Pharmaceuticals, Convergent, Eli Lilly, Fusion Pharmaceuticals, Point Biopharma, Ratio, Telix, and United Health Group*; he has patents for Saposin C and receptors as targets for treatment of benign and malignant disorders (U.S. patent awarded January 23, 2007; patent no. 7,166,691); he has provided expert testimony for Sanofi; he has received reimbursement for travel, accommodations, or expenses from AstraZeneca, Bayer, Lantheus, and Sanofi; and his institution has received research/grant funding from Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, InVita, Janssen, Lantheus, Merck, and Sanofi. Phillip J. Koo has received compensation for a consulting or advisory role from Lantheus, Blue Earth Diagnostics, Merck, Janssen, Pfizer, Astellas, AstraZeneca, Bayer, Novartis, Sanofi, Telix, and Curium. Scott E. Eggener has received compensation for a consulting or advisory role Candel Therapeutics, A3P Biomedical, Cellvax, MetasTx, OptumHealth, and Janssen. Sandy Srinivas has received compensation for a consulting or advisory role from Novartis and Janssen. Scott T. Tagawa has received compensation for a consulting or advisory role from Sanofi, Medivation, Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth, AIkido Pharma, Telix Pharma, Convergent Therapeutics, EMD Serono, Myovant, Merck, Daiichi Sankyo, TransThera, and Regeneron; he is an unpaid consultant for Atlab Pharma, Phosphatase Therapeutics, Amgen, and Ambrx; he and his institution hold patents for biomarkers for sacituzumab govitecan therapy (Immunomedics/Gilead); and his institution has received research funding from Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, Abbvie, Karyopharm, Endocyte, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma, Ambrx, Clarity. Thomas P. Boike has received compensation for a consulting or advisory role from Lantheus, Myovant, Novartis, Pfizer, Janssen, Astellas, Blue Earth, AstraZeneca, Palette Life Sciences, and Boston Scientific. Tanya Dorff has received compensation for a consulting or advisory role from AstraZeneca, Bayer, Janssen, and Sanofi. Tian Zhang has received compensation for a consulting or advisory role from Merck, Exelixis, Sanofi-Aventis, Janssen, AstraZeneca, Pfizer, Amgen, BMS, Dendreon, SeaGen, Eisai, Aveo, Bayer, and Eli Lilly; honoraria from MJH Associates, Vaniam, Aptitude Health, PlatformQ, IntegrityCE, PeerView, and WJ Weiser; and her institution has received research funding from Novartis, Merck, Janssen, AstraZeneca, Pfizer, Tempus, and Eli Lilly. Wendy Poage is an employee of Servier Pharmaceuticals; and she has ownership interests in 3D biopsy.

- ²Department of Urology, University of California San Diego, La Jolla, California
- ³Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
- ⁴Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois
- ⁵Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
- ⁶Department of Urology, University of California at San Francisco, San Francisco, California
- ⁷Yale New Haven Health, New Haven, Connecticut
- ⁸Carolina Urologic Research Center/Genesis Care, Myrtle Beach, South Carolina
- ⁹University Hospitals Seidman Cancer Center, Cleveland, Ohio
- ¹⁰Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, New York
- ¹¹Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
- ¹²Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
- ¹³Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina
- ¹⁴Michigan Healthcare Professionals, Troy, Michigan
- ¹⁵Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California
- ¹⁶Hopkins Kimmel Cancer Center, Baltimore, Maryland
- ¹⁷Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
- ¹⁸Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma
- ¹⁹City of Hope Comprehensive Cancer Center, Duarte, California
- ²⁰Departments of Surgery (Urology), University of Chicago Medical Center, Chicago, Illinois
- ²¹Departments of Radiation Oncology, Urology, and Medicine, University of California San Francisco, San Francisco, California
- ²²Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada
- ²³University of British Columbia, Vancouver, British Columbia, Canada
- ²⁴Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California
- ²⁵Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
- ²⁶Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- ²⁷Department of Urology, NYU Langone Health, New York, New York
- ²⁸Prostate Conditions Education Council, Centennial, Colorado

²⁹Department of Medicine, Division of Hematology-Oncology, VA Greater Los Angeles, Los Angeles, California

³⁰Departments of Medicine and Urology, David Geffen School of Medicine at UCLA, Los Angeles, California

³¹Tulane Cancer Center, New Orleans, Louisiana

³²Keystone Urology Specialists, Lancaster, Pennsylvania

³³UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California

³⁴Division of Medical Oncology, Stanford University Medical Center, Stanford, California

³⁵Department of Medicine, Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington

³⁶Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas

³⁷Banner MD Anderson Cancer Center, Phoenix, Arizona

Abstract

Background: Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are encountering increasingly challenging clinical scenarios, with limited guidance from the current literature.

Materials and Methods: The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management. At the first annual USPCC meeting, areas of controversy and consensus were identified during a 2-day meeting that included expert presentations, full-panel discussions, and postdiscussion responses to questions developed by the USPCC cochairs and session moderators.

Results: This narrative review covers the USPCC expert discussion and perspectives relevant to mCRPC, including neuroendocrine/aggressive-variant prostate cancer (NEPC/AVPC). Areas of broad agreement identified among USPCC experts include the benefits of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with *BRCA1/2* mutations, the use of radioligand therapy in patients with prostate-specific membrane antigen (PSMA)-positive mCRPC, and the need for clinical trials that address real-world clinical questions, including the performance of novel therapies when compared with modern standard-of-care treatment. Ongoing areas of controversy and uncertainty included the appropriateness of PARP inhibitors in patients with non-*BRCA1/2* mutations, the optimal definition of PSMA positivity, and systemic therapies for patients with NEPC/AVPC after progression on platinum-based therapies.

Conclusions: The first annual USPCC meeting identified several areas of controversy in the management of mCRPC, highlighting the urgent need for clinical trials designed to facilitate treatment selection and sequencing in this heterogeneous disease state.

Keywords

prostatic neoplasms; androgen antagonists; radiotherapy; biomarkers; precision medicine

OVER the past decade, treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded rapidly.¹ With the recent addition of so many novel agents, combinations, and drug classes, clinicians are faced with increasingly complex decision-making processes related to the selection and sequencing of systemic therapies. These decisions are further complicated by the availability and integration of molecular targeted imaging and theranostics into clinical practice. Across these new management strategies, level 1 clinical trial evidence is lacking, presenting a challenge for clinicians who manage mCRPC.

In contrast with the bevy of options for castration-resistant prostatic adenocarcinoma, few treatment options are available for less common variants of the disease, such as neuroendocrine prostate cancer (NEPC). The diagnosis of NEPC is currently based on pathologic features showing poorly differentiated neuroendocrine features (typically small-cell carcinoma). In the absence of metastatic biopsy, clinical features of aggressive disease (ie, aggressive-variant prostate cancer [AVPC]) can also be used to identify patients who may benefit from treatment intensification. Both NEPC and AVPC are associated with androgen receptor (AR)–independent features, including loss of expression of luminal prostate and AR signaling markers and simultaneous *RBI*, *PTEN*, and *TP53* tumor suppressor loss. While de novo NEPC/AVPC is considered rare, more recent studies suggest that NEPC/AVPC may be an underrecognized transformation in patients with mCRPC who progress on treatment.² Given the poor prognosis of NEPC and AVPC, standardized approaches to disease identification, monitoring, and treatment are needed to better align with the dynamic morphologic and genomic changes characteristic of NEPC/AVPC transformation.

To address these and other conundrums of advanced prostate cancer (PCa) management, a multidisciplinary panel of PCa experts was convened in 2023, with the goal of identifying areas of consensus and controversy across the spectrum of PCa. At the first annual US Prostate Cancer Conference (USPCC), the topics and discussion were intentionally focused on areas of complexity in the management of PCa. In this manuscript, the second in a 2-part USPCC series, discussions and outcomes related to late-stage PCa—specifically mCRPC and NEPC/AVPC—are reported.

MATERIALS AND METHODS

As described in part 1,³ the USPCC was held on February 18 and 19, 2023, and consisted of 9 sessions on the topics of androgen deprivation therapy (ADT), high-risk PCa, biochemical recurrence, metastatic castration-sensitive PCa, metastasis-directed therapy, NEPC/AVPC, mCRPC, poly(ADP-ribose) polymerase inhibitors (PARPis), and theranostics. These topics were selected collaboratively by USPCC co-chairs and were moderated by USPCC panel members considered experts in each subject. These moderators were responsible for identifying clinical challenges and unanswered questions within the subject area, designing

the discussion agenda, and developing discrete-choice questions discussed qualitatively in this report. Each meeting session included prepared expert presentations, moderated discussions among all USPCC contributors, and anonymous voting. Although voting was encouraged, it was not required that panel members answer all questions. Questions and responses for the sessions on mCRPC, PARPis, theranostics, and NEPC/AVPC can be found in Supplemental Appendix 1 (<http://links.lww.com/JU9/A65>).

The results of the USPCC discussions on mCRPC and NEPC/AVPC are reported here.

RESULTS AND DISCUSSION

mCRPC

Guidance for the selection and sequencing of systemic therapy for mCRPC is limited. Current National Comprehensive Cancer Network (NCCN) guidelines stratify treatment recommendations based on receipt of prior docetaxel and/or prior AR pathway inhibitor (ARPi).⁴ Additional guidance regarding selection of agents across and within drug classes, however, is lacking. This is particularly true for the newest treatment options, including PARPi monotherapy, PARPi combination therapy, and radioligand therapy (RLT). Furthermore, biomarker-driven patient selection in PCa is still in its infancy, and clinical trials are needed to determine which patients will benefit most from newly approved targeted treatment approaches. As such, USPCC discussions about mCRPC centered on appropriate PARPi use, theranostics and RLT, and unmet needs in mCRPC treatment, including investigational therapies and future research priorities.

Homologous Recombination Repair Testing and PARPis.—Between 20% and 25% of patients with advanced PCa have homologous recombination repair (HRR) gene mutations,^{5–7} indicating a potential role for targeted therapy in up to 1 in 5 men with mCRPC. And yet, clinical uptake of genomic testing in patients with PCa is highly heterogeneous in the United States, with studies showing that most men with mCRPC do not receive HRR genetic testing.^{8–11} To address this deficiency, USPCC experts emphasized the need for standardization of somatic tumor testing for HRR mutations in all patients with mCRPC, regardless of prior genetic testing results. Indeed, 81% of USPCC experts indicated that they would recommend repeat genetic testing after development of mCRPC in a patient whose primary tumor was negative for HRR gene mutations. Although metastatic tissue biopsy is the preferred method for molecular evaluation among USPCC experts and guidelines, 59% of USPCC experts indicated that circulating tumor DNA (ctDNA) testing could be used without tissue testing. This recommendation is aligned with NCCN guidelines, which indicate that ctDNA testing may be used when biopsy is not feasible. Importantly, USPCC experts emphasized that serum levels of ctDNA can be dependent on tumor volume, and samples should ideally be collected during radiographic progression to maximize the diagnostic yield.⁴

One major and ongoing question related to the use of PARPis is optimal patient selection, particularly for those with non-*BRCA1/2* HRR gene mutations. Among the 5 current US Food & Drug Administration (FDA) approvals for PARPis in mCRPC, 3 are restricted to tumors with deleterious aberrations in *BRCA1/2* while 2 approvals include a larger panel

of alterations. USPCC panelists noted, however, that PARPis have been associated with the greatest benefit in *BRCA2*-altered tumors, with lower response rates in non-*BRCA2*-altered disease.¹² As a result, USPCC experts were divided on whether PARPi monotherapy should be offered to patients with non-*BRCA1/2*HRR gene mutations: 38% agreed, 38% disagreed, and 16% were not sure. For the most part, USPCC members who agreed that PARPis should be offered to patients with non-*BRCA1/2*HRR gene mutations noted that PARPis would be one of many treatment options discussed as part of shared decision-making.

Another important question addressed during the USPCC meeting was the optimal duration of PARPi therapy in patients with durable responses. In the TRITON and PROfound trials, PARPis were continued until disease progression or unacceptable toxicity,^{13–15} and all PARPis are approved on continuous, daily dosing schedules. Nonetheless, PARPis are associated with progressive myelosuppression and a risk of developing myelodysplastic syndrome/acute myeloid leukemia.¹⁶ In light of these risks, just less than one-third of USPCC members indicated that they would consider a drug holiday to reduce long-term toxicity in patients with deep responses to PARPis. Overall, USPCC experts agreed that, if PARPis were to be withheld or paused for reasons other than toxicity, close follow-up is necessary to ensure prompt reinitiation of PARPi or another systemic therapy in case of disease progression.

Combination Therapy With PARPis and ARPis.—At the time of the meeting, FDA adjudication was still pending for combination therapy with both niraparib plus abiraterone and talazoparib plus enzalutamide. Nevertheless, the trial data were available, and the panel debated the appropriateness of PARPi/ARPi combinations for the various genotypes that were studied in PROPEL, MAGNITUDE, and TALAPRO2. Based on these trial data, 16% of panel members were not sure or abstained when asked whether they would offer PARPi/ARPi combination therapy to patients with *BRCA1/2*-mutated mCRPC, while the remaining 84% of panel members endorsed offering PARPi/ARPi combination therapy to these patients. By contrast, only 27% of panel members indicated that they would offer PARPi/ARPi combination therapy to patients without HRR gene mutations. The FDA decisions for olaparib plus abiraterone and talazoparib plus enzalutamide—which were released after the USPCC meeting—appear to align with the sentiments of the USPCC experts, with approvals limited to patients with *BRCA1/2* mutations (olaparib/abiraterone and niraparib/abiraterone) or deleterious HRR gene mutations (talazoparib/enzalutamide).

Theranostics and RLT.—With the approval of lutetium-177 vipivotide tetraxetan (¹⁷⁷Lu-PSMA-617) for mCRPC along with 3 prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) radiotracers, physicians are now faced with the need to simultaneously integrate new monitoring and treatment standards in a highly heterogeneous population. The challenges are amplified by the contrasting standards used in the 2 reference studies for ¹⁷⁷Lu-PSMA-617. In the phase 3 VISION study, ¹⁷⁷Lu-PSMA-617 with standard of care significantly improved radiographic progression-free survival (PFS) and overall survival (OS) relative to standard of care alone among patients with mCRPC who had received prior treatment with ARPis and taxanes.¹⁷ These results are supported by the phase 2 TheraP trial, which showed that ¹⁷⁷Lu-PSMA-617 improved PSA response and

PFS outcomes compared with cabazitaxel in patients with mCRPC.¹⁸ Both studies mandated confirmation of PSMA expression by PET/CT for eligibility; however, VISION and TheraP classified PSMA positivity differently, complicating the use of PSMA theranostics in clinical practice.

In VISION, patients were considered PSMA-positive if the maximum standardized uptake value (SUV_{max}) for at least 1 tumor lesion was greater than that of the liver parenchyma, with no PSMA-negative lesions (PSMA uptake less than the liver parenchyma) measurable by CT.¹⁷ By contrast, the TheraP protocol used a fixed SUV_{max} cutoff of at least 20 to identify PSMA-positive lesions, excluding patients who had metastatic lesions with PSMA SUV_{max} of 10 or less. Patients with discordant (18)F-fluorodeoxyglucose (FDG)-positive and PSMA-negative lesions were also excluded in TheraP.¹⁸ Panel members felt that the TheraP standard represented more stringent criteria that selected for a population with extremely high PSMA expression, thus accounting for the higher response rates in treated patients.¹⁹

USPCC experts were divided regarding the best standardized criteria for selection of patients for PSMA-targeted RLT, with 44% preferring VISION study protocol, 19% using VISION criteria for PSMA positivity but allowing PSMA-low or PSMA-negative lesions, and only 6% preferring the TheraP criteria. Although the USPCC panel included experts from many of the largest cancer centers in the United States, very few were able to support concomitant PSMA and FDG PET imaging for every patient and thus panelists felt implementation of the TheraP standard was unrealistic in routine clinical practice.

Another practical consideration related to theranostic PCa management is the use of advanced imaging techniques to monitor treatment responses. The USPCC discussed 2 types of imaging that may provide useful response information: PSMA PET/CT and single-photon emission computed tomography (SPECT)/CT obtained from ¹⁷⁷Lu-PSMA gamma emission 24 hours postinfusion, the latter of which allows for dosimetry calculations.²⁰ One of the potential advantages of postinfusion SPECT-based dosimetry is the potential for identification of hyper-responders or nonresponders, which could allow providers to adjust RLT dosing or switch treatments, respectively.^{18,21–23} Most USPCC experts, however, emphasized the need for additional data before postinfusion SPECT is routinely integrated at every visit. PSMA PET was generally viewed as a more practical imaging option, although guidelines are conflicting regarding the use of PSMA PET to monitor response in patients receiving PSMA-directed RLT. NCCN specifies that conventional imaging should be used for treatment response monitoring, and the American Society of Clinical Oncology has recently released a Rapid Recommendation indicating that there is no role for PSMA PET monitoring in patients receiving ¹⁷⁷Lu-PSMA-617.^{4,24,25} By contrast, the Society of Nuclear Medicine and Molecular Imaging Appropriate Use Criteria consider PSMA PET to be appropriate for assessing response to PSMA-based RLT,²⁶ and the RADAR VI panel indicated that PSMA PET may be used for treatment monitoring but should not be used alone to make decisions regarding treatment discontinuation.²⁷ USPCC experts were similarly divided regarding the appropriate use of PSMA PET for response assessment in patients receiving ¹⁷⁷Lu-PSMA-617: 53% of experts believed PSMA PET was appropriate for follow-up monitoring while 39% indicated PSMA PET monitoring should only be

used in research settings. If PSMA PET is used for response assessment, USPPC experts recommended consideration of conventional imaging in addition to PSMA PET every 2 to 3 cycles to monitor for mixed responses in PSMA-negative or PSMA-low lesions.

NEPC and AVPC

Aggressive variants of PCa can emerge during hormonal treatment for metastatic disease.²⁸ This may manifest clinically as histologic transformation from prostate adenocarcinoma to small-cell NEPC, similar to the transformation of lung adenocarcinoma to small-cell lung cancer (SCLC). Patients with small-cell NEPC are often managed using SCLC regimens (ie, first-line platinum-based chemotherapy), which is supported by NCCN guidelines.⁴ However, the diagnosis of NEPC is challenging and relies on metastatic tumor biopsy. In the absence of biopsy, aggressive-variant clinical features have also been used in phase 2 trials to select patients with AVPC for platinum-based chemotherapy. The relative lack of diagnostic criteria and randomized clinical trial data complicate the management of NEPC/AVPC.

Diagnosis and Classification.—Neuroendocrine or small-cell differentiation detected on biopsy tissue remains the undisputed standard for NEPC/AVPC diagnosis. As such, the panel discussed indications for tissue biopsy to assess for the presence of NEPC/AVPC. Most USPPC experts recommended considering a biopsy to evaluate for AVPC in the following scenarios: development of new liver metastases despite low or stable PSA levels (97%), PSMA-negative soft tissue or visceral lesions (83%), and parenchymal brain metastases (61%). Only 17% of USPPC experts recommended biopsies in all patients with castration-resistant PCa.

Given the challenges of metastatic tissue biopsies, USPPC experts discussed the use of liquid biopsies as an option for diagnosing and monitoring mCRPC transformation. Not only do liquid biopsies reduce the burden of tumor biopsy but they can also be used to capture intertumoral and intratumoral heterogeneity and dynamic changes.^{28,29} Commercially available ctDNA tests can identify genomic alterations enriched in NEPC/AVPC (eg, loss of *RBI*, *TP53*, and *PTEN*),^{30,31} and 61% of USPPC experts indicated they use these genomic features to select candidates for platinum-based chemotherapy in patients without histologic features of NEPC on biopsy. In the future, circulating tumor cell liquid biopsies may provide an alternative to ctDNA-based techniques, more reliably identifying NEPC.^{32,33} Until that time, tumor biopsy remains the standard approach.

Because NEPC/AVPC is a highly heterogeneous disease state, disease classification and standardization of nomenclature has thus far been challenging. The WHO classification system fails to capture the broad range of morphologic, genomic, and clinical features that may be present in patients.^{34,35} USPPC experts emphasized the need to assess clinical features in conjunction with pathologic features (eg, morphology and immunohistochemical markers of metastatic biopsies) and molecular markers.

Systemic Therapy.—Systemic therapy for NEPC is generally based on recommendations for SCLC because of the shared pathologic and molecular features across poorly differentiated neuroendocrine carcinomas. Clinically defined AVPC has also been associated

with platinum sensitivity in phase 2 trials. In patients with de novo small-cell carcinoma, initial hormonal therapy should still be considered because of the high likelihood of mixed histologies, and ADT should be continued in those patients who develop treatment-emergent NEPC. There is evidence that cabazitaxel plus carboplatin delays progression in patients with AVPC, and this is currently the only treatment option supported by clinical trial results.³⁶ Because of limited data regarding NEPC/AVPC treatment, next-line therapy after progression on platinum-based chemotherapy remains uncertain. Among those who responded to the question about subsequent treatment after progression on a carboplatin doublet, USPCC experts were evenly split between lurbinectedin (17%), pembrolizumab (14%), taxane chemotherapy (14%), or other treatment (14%). In general, USPCC experts emphasized the urgent need for large, well-controlled trials in patients with NEPC/AVPC to improve the classification and treatment of this disease state.

Looking to the Future: Clinical Trial Design

In many ways, the commercial development of new management options for mCRPC has preceded definitive evidence for the application of these strategies in clinical practice. As such, USPCC experts spent considerable time discussing the need for new, thoughtfully designed studies in the mCRPC setting. When trials for many of the newly approved mCRPC drugs were initially designed, fewer treatment options were available, leading to the use of ARPis as active comparators. Many—but not all—USPCC experts felt that ARPi control arms in populations who have previously received ARPis no longer represent best standard of care because of the increasingly nuanced approach to mCRPC management. As an alternative, USPCC experts advocated for clinical trials to compare investigational therapies with physician's choice, particularly in later-line treatment settings where a number of agents are both available and reasonable. Although some USPCC experts voiced concerns about the challenges of physician's choice arms in clinical trials, including the difficulties with controlling for different comparator treatments, others pointed to the successes of recent phase 3 trials that allowed physician's choice, such as VISION and TRITON3.^{14,17} Furthermore, physician's choice of treatment has been used as a comparator for more than a decade in other heavily pretreated tumor types,^{37–40} suggesting feasibility with careful trial design. Advantages of physician's choice control arms with well-defined standard-of-care options include the use of treatments that are most likely to be used in real-world settings and the potential for faster trial accrual because of increased physician willingness to enroll patients in trials.

CONCLUSIONS

At the first annual USPCC meeting, our multidisciplinary group of experts identified a number of ongoing challenges with the management and monitoring of mCRPC. Given the rapid advancements in the clinical approach to mCRPC, providers who manage PCa are routinely faced with clinical decisions not addressed by the extant literature. Nonetheless, several areas of general consensus were identified among USPCC experts, including the benefits of PARPis and RLT in appropriately selected patients. Ongoing questions and controversies related to mCRPC care include optimal treatment sequencing (particularly in later lines of therapy), patient selection for PARPis and RLT, systemic treatment for

aggressive variants such as NEPC, and optimal dosing and monitoring for RLT. Ongoing clinical trials will address some—but not all—of these challenges, and future clinical trial designs should take into consideration the fast pace of development for mCRPC and the need for adaptability to ensure that study results are applicable to current clinical practice.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

Jessica Martin, PhD, and MJH Life Sciences provided medical writing, editing, and referencing support at the direction of the authors.

FUNDING

AstraZeneca, Bayer, Janssen, Pfizer, and Sanofi provided financial support for the on-site USPPC meeting. The funders had no control, oversight, or other input regarding the faculty invited to attend, the topics covered during the meeting, the questions asked to panel members, or other content discussed during USPPC. The authors developed the manuscript independently without contribution or oversight of the content by any sponsors, who had no role in the manuscript content, development, or approval process.

REFERENCES

1. Sayegh N, Swami U, Agarwal N. Recent advances in the management of metastatic prostate cancer. *JCO Oncol Pract*. 2022;18(1):45–55. [PubMed: 34473525]
2. Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. *J Clin Oncol*. 2018;36(24):2492–2503. [PubMed: 29985747]
3. Crawford ED, Bryce AH, Hussain MH, et al. Expert perspectives on controversies in castration-sensitive prostate cancer management: narrative review and report of the first US prostate cancer conference part 1. *JU Open Plus*. 2024;2.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology (NCCN Guidelines®) prostate cancer; 2022. Version 1.2023. Accessed June 7, 2023. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
5. Chung JH, Dewal N, Sokol E, et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. *JCO Precis Oncol*. 2019;3:1–23.
6. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. *Cell*. 2015;161(5):1215–1228. [PubMed: 26000489]
7. Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. *JCO Precision Oncol*. 2017;2017(1):1–16.
8. Leith A, Ribbands A, Kim J, et al. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan. *Future Oncol*. 2022;18(8):937–951. [PubMed: 35043687]
9. Paller CJ, Antonarakis ES, Beer TM, et al. PCCTC Germline Genetics Working Group. Germline genetic testing in advanced prostate cancer; practices and barriers: survey results from the germline genetics working group of the prostate cancer clinical trials consortium. *Clin Genitourin Cancer*. 2019;17(4):275–282.e1. [PubMed: 31171481]
10. Suri Y, Yasmeh JP, Basu A. Understanding the uptake and challenges of genetic testing guidelines for prostate cancer patients. *Cancer Treat Res Commun*. 2022;32:100588. [PubMed: 35759831]
11. Borno HT, Odisho AY, Gunn CM, Pankowska M, Rider JR. Disparities in precision medicine—examining germline genetic counseling and testing patterns among men with prostate cancer. *Urol Oncol*. 2021;39(4):233.e9–233.e14.

12. Taza F, Holler AE, Fu W, et al. Differential activity of PARP inhibitors in BRCA1-versus BRCA2-altered metastatic castration-resistant prostate cancer. *JCO Precision Oncol.* 2021;5:1200.
13. Abida W, Patnaik A, Campbell D, et al. TRITON2 Investigators. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. *J Clin Oncol.* 2020;38(32):3763–3772. [PubMed: 32795228]
14. Fizazi K, Piulats JM, Reaume MN, et al. TRITON3 Investigators. Rucaparib or physician's choice in metastatic prostate cancer. *N Engl J Med.* 2023;388(8):719–732. [PubMed: 36795891]
15. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. *N Engl J Med.* 2020;382(22):2091–2102. [PubMed: 32343890]
16. Wang C, Li J. Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. *J Clin Pharm Ther.* 2021;46(3):571–584. [PubMed: 33421183]
17. Sartor O, de Bono J, Chi KN, et al. VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. *N Engl J Med.* 2021;385(12):1091–1103. [PubMed: 34161051]
18. Hofman MS, Emmett L, Sandhu S, et al. TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. *Lancet.* 2021;397(10276):797–804. [PubMed: 33581798]
19. Buteau JP, Martin AJ, Emmett L, et al. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). *J Clin Oncol.* 2022;40(6_suppl 1):10.
20. Fanti S, Briganti A, Emmett L, et al. EAU-EANM consensus statements on the role of prostate-specific membrane antigen positron emission tomography/computed tomography in patients with prostate cancer and with respect to [177Lu]Lu-PSMA radioligand therapy. *Eur Urol Oncol.* 2022;5(5):530–536. [PubMed: 35697600]
21. Pathmanandavel S, Crumbaker M, Ho B, et al. Evaluation of (177)Lu-PSMA-617 SPECT/CT quantitation as a response biomarker within a prospective (177)Lu-PSMA-617 and NOX66 combination trial (LuPIN). *J Nucl Med.* 2023;64(2):221–226. [PubMed: 36008120]
22. Peters SMB, Mink MCT, Privé BM, et al. Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation. *EJNMMI Res.* 2023;13(1):6. [PubMed: 36692682]
23. Kurth J, Heuschkel M, Tonn A, et al. Streamlined schemes for dosimetry of (177)Lu-labeled PSMA targeting radioligands in therapy of prostate cancer. *Cancers (Basel).* 2021;13(15):3884. [PubMed: 34359784]
24. Garje R, Rumble RB, Parikh RA. Systemic therapy update on ¹⁷⁷Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO rapid recommendation. *J Clin Oncol.* 2022;40(31):3664–3666. [PubMed: 36112960]
25. Garje R, Hope TA, Rumble RB, Parikh RA. Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Guideline Expert Panel. Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO guideline rapid recommendation Q and A. *JCO Oncol Pract.* 2023;19(3):132–135. [PubMed: 36693228]
26. Jadvar H, Calais J, Fanti S, et al. Appropriate use criteria for prostate-specific membrane antigen PET imaging. *J Nucl Med.* 2022;63(1):59–68. [PubMed: 34593595]
27. Crawford ED, Albala D, Harris R, et al. A clinician's guide to targeted precision imaging in patients with prostate cancer (RADAR VI). *JU Open Plus.* 2023;1(1):e00003.
28. Beltran H, Hruszkewycz A, Scher HI, et al. The role of lineage plasticity in prostate cancer therapy resistance. *Clin Cancer Res.* 2019;25(23):6916–6924. [PubMed: 31363002]
29. Conteduca V, Ku S-Y, Fernandez L, et al. Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. *NPJ Precision Oncol.* 2021;5(1):76.
30. Beltran H, Romanel A, Conteduca V, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. *J Clin Invest.* 2020;130(4):1653–1668. [PubMed: 32091413]

31. Zhao SG, Chen WS, Li H, et al. The DNA methylation landscape of advanced prostate cancer. *Nat Genet.* 2020;52(8):778–789. [PubMed: 32661416]
32. Scher HI, Jendrisak A, Gill A, et al. Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane. *J Clin Oncol.* 2020;38(15_suppl 1):5572.
33. Zhao SG, Sperger JM, Schehr JL, et al. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. *J Clin Invest.* 2022;132(21):e161858. [PubMed: 36317634]
34. Netto GJ, Amin MB, Berney DM, et al. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors. *Eur Urol.* 2022;82(5):469–482. [PubMed: 35965208]
35. Conteduca V, Oromendia C, Eng KW, et al. Clinical features of neuroendocrine prostate cancer. *Eur J Cancer.* 2019;121:7–18. [PubMed: 31525487]
36. Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. *Lancet Oncol.* 2019;20(10):1432–1443. [PubMed: 31515154]
37. Cortes J, O’Shaughnessy J, Loesch D, et al. EMBRACE EIsai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389 Investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet.* 2011;377(9769):914–923. [PubMed: 21376385]
38. Krop IE, Kim S-B, González-Martín A, et al. TH3RESA Study Collaborators. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2014;15(7):689–699. [PubMed: 24793816]
39. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *J Clin Oncol.* 2013;31(5):616–622. [PubMed: 23295794]
40. Olivier T, Haslam A, Prasad V. Reporting of physicians’ or investigators’ choice of treatment in Oncology randomized clinical trials. *JAMA Netw Open.* 2022;5(1):e2144770. [PubMed: 35061042]